Heterogeneity of immunostaining for tumour markers in non-small cell lung carcinoma

European Journal of Cancer

Volumn 40, Issue 3, 2004, Pages 461-466

  Macdonald, C ^a   Michael, A ^a   Colston, K ^a   Mansi, J ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

bc1 2; Carcinoma; Immunohistochemistry; Ki 67; Lung; p53; Prognostic significance

Indexed keywords

KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER;

ANALYTIC METHOD; APOPTOSIS; ARTICLE; CELL HETEROGENEITY; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 1642513828     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2003.10.019     Document Type: Article

References (25)

1. Hwang J.H., Lim S.C., Kim Y.C., Park K.O., Ahn S.J., Chung W.K. Apoptosis and bcl-2 expression as predictors of survival in radiation treated non small cell lung cancer. Int J Radiat Oncol Biol Phys. 50:2001;13-18.
2. Tanaka F., Otake Y., Yanagihara K.et al. Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non small cell lung cancer. Br J Cancer. 84:2001;263-269.
3. Komaki R., Milas L., Ro J.Y.et al. Prognostic biomarker study in pathologically staged N1non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 40:1998;787-796.
4. Ishida H., Irie K., Itoh T., Furukawa T., Tokunaga O. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. Cancer. 80:1997;1034-1045.
5. Medhi S.A., Etzell J.E., Newman N.B., Weider N., Kohman L.J., Graziano S.L. Prognostic significance of Ki-67 immunostaining and symptoms in resected stage I and II non-small cell lung cancer. Lung Cancer. 20:1998;99-108.
6. Nguyen V.N., Mirejovsky P., Miresjovesky T., Melinova L., Mandys V. Expression of cyclin D1, Ki-67 and PCNA in non-small cell lung cancer. prognostic significance and comparison with p53 and bcl-2 Acta Histochem. 102:2000;323-338.
7. Tanaka F., Yanagihara K., Yamada T.et al. Prognostic factors in patients with resected pathologic (p-) T1-2N1M0 non-small cell lung cancer (NSCLC). Eur J Cardiothorac Surg. 19:2001;555-561.
8. Cagini L., Monacelli M., Giustozzi G.et al. Biological prognostic factors for early stage completely resected non-small cell lung cancer. J Surg Oncol. 74:2000;53-60.
9. Fontanini G., Vignati S., Bigini D. Bcl-2 protien. a prognostic factor inversely correlated to p53 in non-small-cell lung cancer Br J Cancer. 71:1995;1003-1007.
10. Harpole D., Herndon J., Wolfe W.G., Iglehart J.D., Marks J.R. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res. 55:1995;51-56.
11. Chen Y., Sato M., Fujimura S.et al. Expression of Bcl-2, Bax, and p53 proteins in carcinogenesis of squamous cell lung cancer. Anticancer Res. 19:1999;1351-1356.
12. Hashimoto T., Tokuchi Y., Hayashi M.et al. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. Cancer Res. 59:1999;5572-5577.
13. Carvalho P.E., Antonangelo L., Bernardi F.D.et al. Useful prognostic panel markers to express the biological tumor status in resected lung adenocarcinomas. Jpn J Clin Oncol. 30:2000;478-486.
14. Lavezzi A.M., Santambrogio L., Bellaviti N.et al. Prognostic significance of different biomarkers in non-small cell lung cancer. Oncol. Rep. 6:1999;819-825.
15. Langendijk H., Thunnissen E., Arends J.W.et al. Cell proliferation and apoptosis in stage III inoperable non-small cell lung carcinoma treated by radiotherapy. Radiother Oncol. 56:2000;197-207.
16. Cox G., Walker R.A., Muller S., Abrams K.R., Steward W.P., O'Bryne K.J. Does immunointensity account for the difference in prognostic significance of Bcl-2 expression in non-small cell lung cancer? Pathol Oncol Res. 6:2000;87-92.
17. Rhodes A., Jasani B., Barnes D.M., Bobrow L.G., Miller K.D. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice. interlaboratory variance in the sensitivity of detection and evaluation of scoring systems J Clin Pathol. 53:2000;125-130.
18. Greatens T.M., Niehans G.A., Rubins J.B.et al. Do molecular markers predict survival in non-small-cell lung cancer? Am J Respir Crit Care Med. 157(4 Pt 1):1998;1093-1097.
19. Huncharek M., Kupelnick B., Geschwind J.F., Caubet J.F. Prognostic significance of p53 mutations in non-small cell lung cancer. a meta analysis of 829 cases from eight published studies Cancer Lett. 153:2000;219-226.
20. Detre S., Saccani Jotti G., Dowsett M. A "quickscore" method for immunohistochemical semiquantitation. validation for oestrogen receptor in breast carcinoms J Clin Pathol. 48:1995;876-879.
21. Bozzetti C., Franciosi V., Crafa P.et al. Biological variables in non-small cell lung cancer: comparison between immunocytochemical determination on fine needle aspirates from surgical specimens and immunohistochemical determination on tissue sections. Lung Cancer. 29:2000;33-41.
22. Lavertu P., Adelstein D.J., Myles J., Secic M. P53 and Ki-67 as outcome predictors for advanced squamous cell cancers of the head and neck treated with chemotherapy. Laryngoscope. 111:2001;1878-1892.
23. Cadwell C., Zambetti G.P. The effects of wild-type p53 tumour suppressor activity and mutant p53 gain-of-function on cell growth. Gene. 277:2001;15-30.
24. Bozzetti C., Nizzoli R., Guazzi A.et al. Biological parameters on computed tomography guided fine needle aspiration biopsy from peripheral primary non-small cell lung cancer. Lung Cancer. 35:2002;243-247.
25. Han H., Landreneau R.J., Santucci T.S.et al. Prognostic value of immunohistochemical expressions of p53, HER-2/neu and bcl-2 in stage I non-small-cell cancer. Hum Pathol. 33:2002;105-110.